Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

ERS Congress 2024

Keep up to date on the latest news from the annual European Respiratory Society conference.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in:

Open Access 01-12-2023 | Metastasis | Research

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in liver metastasis lesions after colon radical operation

Authors: Yan Qiao, Xiaomeng Li, Yongquan Hu, Pu Guo, Hengchao Liu, Hong Sun

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Purpose

Our study was to investigate the correlation correlation between FDG uptake and PD-L1 expression of liver metastasis in patients with colon cancer, and to determine the value of FDG-PET in predicting PD-L1 expression in liver metastasis of colon cancer.

Methods

A total of 72 patients with confirmed liver metastasis of colon cancer were included in this retrospective study. The PD-L1 expression and immune cell infiltrating of tumors were determined through immunohistochemistry staining. The SUVmax of liver metastasis lesions were assessed using 18 F-FDG PET/CT. The correlation between PD-L1 expression and the clinicopathological were evaluated by the Cox proportional hazards model and the Kaplan-Meier survival analysis.

Results

PD-L1 expression was significantly correlated with FDG uptake (SUVmax), tumor size, differentiation, survival and cytotoxic T cells infiltration in liver metastasis of colon cancer (P < 0.05). And liver metastases with high counts of infiltrating cytotoxic T cells showed greater FDG uptake than those with low counts of infiltrating cytotoxic T cells. The SUVmax of liver metastases and the degree of differentiation of metastases were closely related to PD-L1 expression, and were independent risk factors.The combined assessment of SUVmax values and tthe degree of differentiation of metastase can help determine PD-L1 expression in liver metastasis of colon cancer.

Conclusions

FDG uptake in liver metastasis of colon cancer was positively correlated with the PD-L1 expression and the number of cytotoxic T cells infiltration. The joint evaluation of two parameters, SUVmax and degree of differentiation, can predict PD-L1 expression in liver metastases.
Literature
1.
Padmanabhan C, Nussbaum DP, D’Angelica M. Surgical Management of Colorectal Cancer Liver Metastases. Surg Oncol Clin N Am. 2021;30(1):1–25.CrossRefPubMed
2.
Saad AM, Abdel-Rahman O. Initial systemic chemotherapeutic and targeted therapy strategies for the treatment of colorectal cancer patients with liver metastases. Expert Opin Pharmacother. 2019;20(14):1767–75.CrossRefPubMed
3.
Zeng X, Ward SE, Zhou J, Cheng ASL. Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives. Cancers (Basel) 2021, 13(10).
4.
Kanani A, Veen T, Soreide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg. 2021;108(12):1417–25.CrossRefPubMed
5.
6.
7.
Woodford R, Zhou D, Lord SJ, Marschner I, Cooper WA, Lewis CR, John T, Yang JC, Lee CK. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. Future Oncol. 2022;18(14):1793–9.CrossRefPubMed
8.
Zhou QH, Li KW, Chen X, He HX, Peng SM, Peng SR, Wang Q, Li ZA, Tao YR, Cai WL et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer 2020, 8(1).
9.
Siggelkow W, Rath W, Buell U, Zimny M. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):118–24.
10.
Zhou X, Chen R, Xie W, Ni Y, Liu J, Huang G. Relationship between 18F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas. J nuclear medicine: official publication Soc Nuclear Med. 2014;55(11):1766–71.CrossRef
11.
Li J, Ge S, Sang S, Hu C, Deng S. Evaluation of PD-L1 expression level in patients with Non-Small Cell Lung Cancer by (18)F-FDG PET/CT Radiomics and Clinicopathological characteristics. Front Oncol. 2021;11:789014.CrossRefPubMedPubMedCentral
12.
Chen R, Zhou X, Liu J, Huang G. Relationship between the expression of PD-1/PD-L1 and (18)F-FDG uptake in bladder cancer. Eur J Nucl Med Mol Imaging. 2019;46(4):848–54.CrossRefPubMed
13.
Togo M, Yokobori T, Shimizu K, Handa T, Kaira K, Sano T, Tsukagoshi M, Higuchi T, Yokoo S, Shirabe K, et al. Diagnostic value of (18)F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8(+)tumour-infiltrating lymphocytes in oral squamous cell carcinoma. Br J Cancer. 2020;122(11):1686–94.CrossRefPubMedPubMedCentral
14.
Wang X, Li R, Chen R, Huang G, Zhou X, Liu J. Prognostic values of TIGAR expression and (18)F-FDG PET/CT in Clear Cell Renal Cell Carcinoma. J Cancer. 2020;11(1):1–8.CrossRefPubMedPubMedCentral
15.
Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, Yamashita K, Saito T, Tanaka K, Takahashi T, et al. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer Sci. 2020;111(4):1103–12.CrossRefPubMedPubMedCentral
16.
17.
Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, Shin JS, O’Toole S, Anderson L, Scolyer RA, et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53(2):141–56.CrossRefPubMed
18.
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–21.CrossRefPubMedPubMedCentral
19.
20.
Chen M, Liu H, Li Z, Ming AL, Chen H. Mechanism of PKM2 affecting cancer immunity and metabolism in Tumor Microenvironment. J Cancer. 2021;12(12):3566–74.CrossRefPubMedPubMedCentral
21.
Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of oncology: official journal of the European Society for Medical Oncology. 2016;27(3):409–16.CrossRefPubMed
22.
Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–21.CrossRefPubMed
23.
Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, Jin X, Liu J, Mo S, Zhang T, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9(1):873.CrossRefPubMedPubMedCentral
24.
Desbois M, Wang Y. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. Immunol Rev. 2021;302(1):241–58.CrossRefPubMed
25.
Pijl JP, Nienhuis PH, Kwee TC, Glaudemans A, Slart R, Gormsen LC. Limitations and Pitfalls of FDG-PET/CT in infection and inflammation. Semin Nucl Med. 2021;51(6):633–45.CrossRefPubMed
26.
Raskov H, Orhan A, Christensen JP, Gogenur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359–67.CrossRefPubMed
27.
Wei C, Ma Y, Wang F, Liao Y, Chen Y, Zhao B, Zhao Q, Wang D, Tang D. Igniting Hope for Tumor Immunotherapy: promoting the “Hot and Cold” Tumor Transition. Clin Med Insights Oncol. 2022;16:11795549221120708.CrossRefPubMedPubMedCentral
28.
Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, Fan Y, Chan NT, Ma L, Liu J, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22(9):1064–75.CrossRefPubMedPubMedCentral
Metadata
Title
Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in liver metastasis lesions after colon radical operation
Authors
Yan Qiao
Xiaomeng Li
Yongquan Hu
Pu Guo
Hengchao Liu
Hong Sun
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11014-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Neoadjuvant Chemoradiation for Rectal Cancer Achieves Satisfactory Tumour Regression and Local Recurrence – Result of a Dedicated Multi-disciplinary Approach from a South Asian Centre

Research

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

Research

Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study

Research

Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma

Research

A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score

Research

Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity